0001816590-26-000020
SEC filingCOMPASS Pathways plc (CMPS), a clinical-stage biotech focused on mental health treatments, reported a net loss of $287.9 million for FY 2025, up from $155.1 million in FY 2024, driven by a $122.6 million non-cash fair value loss on warrant liabilities from the January 2025 financing. Total operating expenses remained stable at $179.0 million, with R&D at $118.4 million (down slightly from $119.0 million) and G&A at $60.6 million (up from $59.2 million). No revenue was generated, consistent with pre-commercial status. Key drivers included Phase 3 TRD trial progress, PTSD Phase 2b/3 initiation, and commercial preparations. Cash and equivalents stood at $149.6 million as of Dec 31, 2025, with total cash, equivalents, and restricted cash at $220.6 million. Post-period, February 2026 offering and warrant exercises added ~$343.7 million net proceeds, extending runway into 2028. Forward-looking, NDA submission targeted Q4 2026 post-26-week COMP006 data in Q3 2026; success hinges on regulatory approvals, rescheduling, and commercialization amid high R&D burn ($157.2 million ops cash use).
COMPASS Pathways reported FY2025 net loss of $287.9M, widening 85% YoY from $155.1M, primarily due to $122.6M non-cash warrant liability fair value loss. Operating loss stable at $179.0M (flat YoY), with R&D $118.4M (-0.5%) and G&A $60.6M (+2.4%). No revenue as pre-commercial. Cash burn intensified with ops cash use $157.2M (vs $119.2M prior). Balance sheet strengthened by $149.6M cash/equivalents; post-period financings extend runway to 2028. Phase 3 TRD trials met primary endpoints; NDA Q4 2026 targeted.
No revenue generated in FY2025 or prior, consistent with clinical-stage focus. Future revenue contingent on COMP360 approval in TRD/PTSD; commercialization prep ongoing, targeting U.S. launch readiness end-2026 if approved.
N/A - pre-revenue. Operating margin negative at -100% implicitly. Expenses disciplined amid trials; R&D stable despite Phase 3 completion/enrollment. Warrant volatility drove net loss expansion; non-cash.
Ops cash use $157.2M (vs $119.2M), financing inflow $140.7M (ATM/equity). Net cash decrease $15.5M; ending total cash/restricted $220.6M. Debt: $31.6M term loan (Hercules). Shareholders' deficit -$52.8M; total assets $210.3M, liabilities $263.2M (warrants $203.7M). Post-Q4 financings bolster liquidity into 2028.
NDA submission Q4 2026 post-COMP006 26-week data Q3 2026. PTSD Phase 2b/3 initiated post-IND clearance. Commercial readiness accelerating; risks include regulatory delays, rescheduling, competition. Cash supports ops into 2028; additional funding possible via PIPE warrants ($122.4M potential).